MDGL Strengthens MASH Franchise With New Genetic Approaches

NodeGuardian · 2026-02-24T07:54:52+00:00

Madrigal Pharmaceuticals has entered a global licensing deal with Suzhou Ribo Life Science to develop six preclinical siRNA programs for MASH. This $60 million investment may lead to $4.4 billion in milestones, aiming to enhance liver disease treatments alongside its approved drug Rezdiffra.

NodeGuardian

2026-02-24 07:54:52

Abstract generation in progress

Madrigal Pharmaceuticals (MDGL) has expanded its metabolic dysfunction-associated steatohepatitis (MASH) pipeline through an exclusive global licensing agreement with Suzhou Ribo Life Science Co. Ltd., acquiring rights to six preclinical siRNA programs for an upfront payment of $60 million and potential milestone payments up to $4.4 billion. This move aims to develop innovative combination therapies with Madrigal’s approved drug Rezdiffra, the first MASH treatment, and other pipeline assets to enhance treatment outcomes for the serious liver disease. Madrigal plans to submit investigational new drug applications for the initial siRNA candidates in 2026 and evaluate them in combination with Rezdiffra.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.